Indoco Remedies Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹475.61 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.79 per cent from ₹445.36 crore. This corresponds to a year-on-year *(YoY) growth of 21.89 per cent.
Operating Profit
Operating Profit stands at ₹49.71 crore, reflecting a quarter-on-quarter *(QoQ) increase of 96.02 per cent from ₹25.36 crore. This corresponds to a year-on-year *(YoY) growth of 6,473.08 per cent.
PBDT
PBDT stands at ₹7.49 crore, reflecting a quarter-on-quarter *(QoQ) increase of 970.00 per cent from ₹0.70 crore. This corresponds to a year-on-year *(YoY) growth of 144.74 per cent.
Profit Before Tax
Profit Before Tax stands at ₹-25.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 20.15 per cent from ₹-31.31 crore. This corresponds to a year-on-year *(YoY) growth of 45.08 per cent.
Net Profit
Net Profit stands at ₹-23.68 crore, reflecting a quarter-on-quarter *(QoQ) increase of 19.59 per cent from ₹-29.45 crore. This represents a 42.72 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Indoco Remedies Ltd News
Indoco Remedies Ltd Earnings
- YOY
- QOQ
Indoco Remedies Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Indoco Remedies Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Indoco Remedies Ltd Financial Reports
Indoco Remedies Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Indoco Remedies | -0.90% | 1.11% | 13.08% | 24.66% | 3.90% | -30.28% |
| Solara Active | -2.10% | -0.64% | 5.57% | 20.76% | -1.48% | -10.98% |
| Hikal | -1.08% | 1.86% | 16.38% | 34.14% | -2.82% | -37.00% |
| Venus Remedies | -5.00% | -9.75% | 19.52% | 92.20% | 133.63% | 290.07% |
| Hester Bios | 2.42% | -0.32% | 12.67% | 54.84% | 39.93% | 21.87% |
| NGL Fine Chem | -3.93% | -2.47% | 12.80% | 34.02% | 109.25% | 142.34% |
| Windlas Biotech | 1.12% | 0.23% | 6.78% | 11.10% | 8.08% | -4.62% |
Company Info
Company Information
Chairman & Non Executive Dir. : Suresh G Kare
ED / MD / Promoter : Aditi Kare Panandikar
Joint MD & Executive Director : Sundeep V Bambolkar
Non-Exec & Non-Independent Dir : Anand Nadkarni
Independent Non Exe. Director : Satish Shenoy
Independent Non Exe. Director : Ajay Mulgaokar
Independent Non Exe. Director : Vasudha V Kamat
Independent Non Exe. Director : Abhijit Y Gore
CS / Compliance Officer / Legal Head : RAMANATHAN HARIHARAN